Altimmune, Inc. - Common Stock (ALT)
Frequently Asked Questions About Altimmune, Inc. - Common Stock (ALT)
Are there any recent news highlights about Altimmune?
Recent news highlights about Altimmune typically revolve around clinical trial updates, partnerships, and advancements in product development. The company regularly publishes press releases to inform stakeholders about significant milestones, including regulatory filings, data presentations, and strategic collaborations that can impact its growth trajectory.
How does Altimmune contribute to public health?
Altimmune contributes to public health by developing innovative therapies and vaccines aimed at controlling and preventing infectious diseases and treating conditions like cancer and obesity. By focusing on improving immune responses through advanced drug delivery mechanisms, Altimmune plays a critical role in addressing urgent health challenges and improving patient outcomes.
How does Altimmune engage with its investors?
Altimmune engages with its investors through regular updates, earnings calls, and presentations at industry conferences. The company prioritizes transparency by providing insights into its clinical progress, financials, and strategic initiatives, fostering an informed investor base committed to its growth journey.
How does Altimmune's technology differ from traditional vaccines?
Altimmune's technology is focused on non-invasive delivery methods, particularly intranasal and oral routes, which differentiate it from traditional vaccines that often require injections. This approach aims to enhance immune responses while improving patient comfort and adherence, potentially leading to better overall vaccination rates.
How has Altimmune performed financially?
Altimmune's financial performance has varied over the years, primarily influenced by its investment in R&D and the progress of its clinical trials. The company periodically reports its financial results, including revenues from any collaborations or grants, R&D expenditures, and overall cash burn rate, which are key metrics for investors to assess the company's financial health.
What are Altimmune's competitive advantages?
Altimmune's competitive advantages include its proprietary drug delivery platforms that enhance patient compliance, a seasoned management team with extensive industry experience, and a diverse pipeline of innovative therapies positioned to address significant medical needs. These factors together give Altimmune a strong foundation for potential success in the biopharmaceutical market.
What are Altimmune's goals for the future?
Altimmune aims to advance its innovative product pipeline, specifically targeting the approval of its therapeutic and vaccine candidates in the coming years. The company is focused on addressing significant public health needs, particularly in infectious diseases and cancer, while fostering strategic collaborations that enhance its research capabilities and market reach.
What are Altimmune's primary products?
Altimmune’s primary products include its lead candidate, T-cell Immunotherapy, which is designed to enhance the body’s immune response against tumors, and its intranasal COVID-19 vaccine candidate, AdCOVID. Additionally, the company is developing treatments for chronic hepatitis B and obesity through its innovative drug delivery platforms like the HUMBLE and Peptide technology.
What challenges does Altimmune face?
Altimmune faces several challenges, including the competitive landscape of the biopharmaceutical industry, regulatory hurdles for its product candidates, and the need for substantial funding to support ongoing clinical trials. Additionally, market acceptance of new drug delivery technologies and potential reimbursement issues are critical factors that can affect the company's success.
What clinical trials is Altimmune involved in?
Altimmune is currently involved in several clinical trials, primarily assessing its COVID-19 vaccine candidate, AdCOVID, as well as therapeutic candidates for hepatitis B and obesity. These trials aim to evaluate the safety, efficacy, and optimal dosing of these innovative treatments and are critical for advancing the products toward regulatory approval.
What does Altimmune, Inc. do?
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic products to treat infectious diseases and cancer. The company utilizes its proprietary platform technology to create treatments that enhance the immune system's ability to fight off diseases, with a particular emphasis on intranasal and oral administration routes for improved patient compliance and efficacy.
What is AdCOVID?
AdCOVID is Altimmune's intranasal vaccine candidate developed to provide protection against COVID-19. Utilizing a novel adenoviral vector, AdCOVID aims to elicit robust immune responses, including mucosal immunity, which is vital for preventing viral entry and transmission in the respiratory tract.
What is the company's strategy for growth?
Altimmune's growth strategy focuses on advancing its clinical pipeline, pursuing strategic collaborations, and expanding its portfolio through innovative therapies targeting high-demand therapeutic areas. The company aims to leverage its proprietary technologies to establish a competitive position within the biotechnology sector while expanding its market opportunities.
What is the significance of Altimmune's pipelines?
The significance of Altimmune's pipelines lies in their potential to address unmet medical needs in infectious diseases, cancer, and metabolic disorders. By innovating in drug delivery and therapeutic design, Altimmune aims to provide safer, more effective treatment options that can improve patient outcomes and contribute to public health.
What is the ticker symbol for Altimmune, Inc.?
The ticker symbol for Altimmune, Inc. is ALT. The company is traded on the Nasdaq stock exchange, allowing investors to buy and sell shares as it responds to the evolving landscape of the biopharmaceutical industry.
What partnerships does Altimmune have?
Altimmune has established several strategic partnerships with academic institutions and industry collaborators to enhance its research capabilities and accelerate product development. These partnerships focus on leveraging complementary expertise, sharing resources, and co-developing new therapeutic approaches for complex diseases.
When was Altimmune founded?
Altimmune, Inc. was founded in 2011. Since its inception, the company has focused on developing next-generation therapeutics targeting critical unmet medical needs, primarily in the fields of infectious diseases and oncology, using innovative delivery mechanisms.
Where is Altimmune, Inc. headquartered?
Altimmune, Inc. is headquartered in Gaithersburg, Maryland, USA. This location places the company within a vibrant biotech hub, enabling it to leverage regional resources and talent as it advances its research and development efforts.
Who are the key executives at Altimmune?
Key executives at Altimmune, Inc. include Dr. Gallogly as the President and CEO and various leaders with expertise in pharmaceutical development and business operations. The experience and vision of its leadership team are central to guiding the company through clinical development phases and strategic partnerships.
What is the current price of Altimmune, Inc. - Common Stock?
The current price of Altimmune, Inc. - Common Stock is 4.515
When was Altimmune, Inc. - Common Stock last traded?
The last trade of Altimmune, Inc. - Common Stock was at 3:33 pm EDT on April 3rd, 2025
What is the market capitalization of Altimmune, Inc. - Common Stock?
The market capitalization of Altimmune, Inc. - Common Stock is 321.13M
How many shares of Altimmune, Inc. - Common Stock are outstanding?
Altimmune, Inc. - Common Stock has 71.12M shares outstanding.